Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA : revenue, balance sheet and financial ratios

SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA is a French company founded 8 years ago, specialized in the sector Gestion de fonds. Based in PARIS (75014), this company of category PME shows in 2024 a net income positive of 48 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-11

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA (SIREN 834495210)
Indicator 2024 2023
Revenue N/C N/C
Net income 47 936 € 222 €
EBITDA -36 253 € -50 517 €
Net margin N/C N/C

Revenue and income statement

In 2024, SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA generates positive net income of 48 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2023-2024: 222 € -> 48 k€.

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-36 253 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-36 253 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

47 936 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 31%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 72%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 4.3 years of cash flow to repay all financial debt. This ratio remains within usual banking standards.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

31.156%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

72.101%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

4.342

Solvency indicators evolution
SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA

Sector positioning

Debt ratio
31.16 2024
2023
2024
Q1: 0.0
Med: 8.28
Q3: 92.71
Average

In 2024, the debt ratio of SPFPLARL DE PHARMACIENS D... (31.16) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
72.1% 2024
2023
2024
Q1: 4.63%
Med: 48.43%
Q3: 87.31%
Good

In 2024, the financial autonomy of SPFPLARL DE PHARMACIENS D... (72.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
4.34 years 2024
2023
2024
Q1: -0.01 years
Med: 0.0 years
Q3: 3.01 years
Average

In 2024, the repayment capacity of SPFPLARL DE PHARMACIENS D... (4.34) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 540.34. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

540.343

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-2.157

Liquidity indicators evolution
SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA

Sector positioning

Liquidity ratio
540.34 2024
2023
2024
Q1: 100.71
Med: 472.45
Q3: 3122.85
Good +16 pts over 2 years

In 2024, the liquidity ratio of SPFPLARL DE PHARMACIENS D... (540.34) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Interest coverage
-2.16x 2024
2023
2024
Q1: -71.11x
Med: 0.0x
Q3: 0.0x
Average

In 2024, the interest coverage of SPFPLARL DE PHARMACIENS D... (-2.2x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 335 days. Excellent situation: suppliers finance 335 days of the operating cycle (retail model).

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

335 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA

Positioning of SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA in its sector

Comparison with sector Gestion de fonds

Valuation estimate

Based on 62 transactions of similar company sales in 2024, the value of SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA is estimated at 354 307 € (range 100 597€ - 701 920€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2024
62 tx
100k€ 354k€ 701k€
354 307 € Range: 100 597€ - 701 920€
NAF 5 année 2024

Valuation method used

Net Income Multiple
47 936 € × 7.4x = 354 307 €
Range: 100 597€ - 701 920€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 62 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Gestion de fonds)

Compare SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA with other companies in the same sector:

Voir toutes les statistiques du secteur Gestion de fonds

Frequently asked questions about SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA

What is the revenue of SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA ?

The revenue of SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA is not publicly disclosed (confidential accounts filed with INPI).

Is SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA profitable?

Yes, SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA generated a net profit of 48 k€ in 2024.

Where is the headquarters of SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA ?

The headquarters of SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA is located in PARIS (75014), in the department Paris.

Where to find the tax return of SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA ?

The tax return of SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA operate?

SPFPLARL DE PHARMACIENS D'OFFINCINE GUILLAUME PEZZANA operates in the sector Gestion de fonds (NAF code 66.30Z). See the 'Sector positioning' section above to compare the company with its competitors.